High Quality Stocks
VX1.DE is part of our High Quality Stocks screen, meaning it meets strict criteria for profitability, capital efficiency, and long-term growth consistency.
VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Price & Overview
FRA:VX1 • US92532F1003
Current stock price
373.75 EUR
-2.75 (-0.73%)
Last:
The current stock price of VX1.DE is 373.75 EUR. Today VX1.DE is down by -0.73%. In the past month the price decreased by -4.55%. In the past year, price decreased by -10.24%.
VX1.DE Key Statistics
52-Week Range312.65 - 447
Current VX1.DE stock price positioned within its 52-week range.
1-Month Range368.4 - 433.25
Current VX1.DE stock price positioned within its 1-month range.
- Market Cap
- 94.944B
- P/E
- 23.72
- Fwd P/E
- 22.53
- EPS (TTM)
- 15.76
- Dividend Yield
- N/A
VX1.DE Stock Performance
Today
-0.73%
1 Week
-1.48%
1 Month
-4.55%
3 Months
-7.20%
Longer-term
6 Months +6.70%
1 Year -10.24%
2 Years +1.77%
3 Years +21.55%
5 Years +108.82%
10 Years N/A
VX1.DE Stock Chart
VX1.DE Stock Screens
VX1.DE currently appears in the following ChartMill screener lists.
VX1.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VX1.DE. When comparing the yearly performance of all stocks, VX1.DE is a bad performer in the overall market: 84.36% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
VX1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE. VX1.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
VX1.DE Earnings
On February 12, 2026 VX1.DE reported an EPS of 5.03 and a revenue of 3.19B. The company missed EPS expectations (-2.79% surprise) and missed revenue expectations (-1.51% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateFeb 12, 2026
PeriodQ4 / 2025
EPS Reported$5.03
Revenue Reported3.19B
EPS Surprise -2.79%
Revenue Surprise -1.51%
VX1.DE Forecast & Estimates
40 analysts have analysed VX1.DE and the average price target is 461.23 EUR. This implies a price increase of 23.41% is expected in the next year compared to the current price of 373.75.
For the next year, analysts expect an EPS growth of 5.3% and a revenue growth 8.81% for VX1.DE
Analysts
Analysts82
Price Target461.23 (23.41%)
EPS Next Y5.3%
Revenue Next Year8.81%
VX1.DE Groups
Sector & Classification
VX1.DE Financial Highlights
Over the last trailing twelve months VX1.DE reported a non-GAAP Earnings per Share(EPS) of 15.76. The EPS increased by 6248.28% compared to the year before.
Income Statements
Revenue(TTM)12.00B
Net Income(TTM)3.95B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 32.94% | ||
| ROA | 15.42% | ||
| ROE | 21.18% | ||
| Debt/Equity | 0.01 |
Chartmill High Growth Momentum
EPS Q2Q%26.38%
Sales Q2Q%9.55%
EPS 1Y (TTM)6248.28%
Revenue 1Y (TTM)8.9%
VX1.DE Ownership
Ownership
Inst Owners97.75%
Shares254.03M
Float253.51M
Ins Owners0.15%
Short Float %N/A
Short RatioN/A
VX1.DE Competitors/Peers
The largest stocks on the EU markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.56 | 41.868B | ||
| 1AE | ARGENX SE | 28.33 | 41.856B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.453B | ||
| ABVX | ABIVAX SA | N/A | 8.352B | ||
| 2X1 | ABIVAX SA | N/A | 8.281B | ||
| GXE | GALAPAGOS NV | N/A | 1.619B | ||
| GLPG | GALAPAGOS NV | N/A | 1.607B | ||
| NANO | NANOBIOTIX | N/A | 1.243B | ||
| PHARM | PHARMING GROUP NV | 43.78 | 1.023B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.007B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 996.493M | ||
| 6IV | INVENTIVA SA | N/A | 981.43M | ||
| PHGN | PHARMING GROUP NV | 41.08 | 975.297M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About VX1.DE
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Company Info
IPO: 1991-07-24
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS US
Employees: 6400
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What does VERTEX PHARMACEUTICALS INC do?
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,400 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
What is the current price of VX1 stock?
The current stock price of VX1.DE is 373.75 EUR. The price decreased by -0.73% in the last trading session.
Does VERTEX PHARMACEUTICALS INC pay dividends?
VX1.DE does not pay a dividend.
What is the ChartMill rating of VERTEX PHARMACEUTICALS INC stock?
VX1.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the expected growth for VX1 stock?
The Revenue of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 8.81% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is VERTEX PHARMACEUTICALS INC worth?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a market capitalization of 94.94B EUR. This makes VX1.DE a Large Cap stock.